Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 10.97
+0.06 (0.55%)
Jul 6, 2026, 9:49 AM EST
Satellos Bioscience Earnings Call Transcripts
Fiscal Year 2026
-
A novel small molecule therapy targeting muscle regeneration in DMD is advancing through two phase II trials, showing promising preclinical and clinical results, including sustained strength gains and a favorable safety profile. Full enrollment and top-line data are expected by year-end, with regulatory and financial milestones on track.
-
A novel oral therapy for Duchenne muscular dystrophy is advancing through phase II trials, showing rapid, durable improvements in muscle strength and favorable safety. Data from pediatric and adult studies are expected in 2026, with accelerated approval targeted for 2027.